Status:
COMPLETED
A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis
Lead Sponsor:
Centocor, Inc.
Collaborating Sponsors:
Centocor BV
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of the study is to evaluate the effectiveness and safety of CNTO 1275 in patients with Multiple Sclerosis
Detailed Description
Multiple sclerosis (MS) is a life-long disease that usually starts in young adults. In MS, inflammation and damage to nerve cells occur in the brain and spinal cord. Symptoms of MS are quite variable ...
Eligibility Criteria
Inclusion
- Have a definite diagnosis of Relapsing remitting Multiple Sclerosis
- Have a history of at least 1 of the following:a. A minimum of 2 relapses of MS within the previous 2 years but not within the 1-month period prior to screening. b. A relapse of MS within the previous 6 months but not within the 1-monthperiod prior to screening
Exclusion
- Have a CNS disease (eg, CNS lymphoma, systemic lupus erythematous)
- Have significant bulbar involvement of MS or other neurologic deficits
- Have a decubitus ulcer
- Have received immunomodulatory therapies within 3 months of screening
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2006
Estimated Enrollment :
249 Patients enrolled
Trial Details
Trial ID
NCT00207727
Start Date
July 1 2004
End Date
August 1 2006
Last Update
April 23 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.